NCT06423144View on ClinicalTrials.gov

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Not yet recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

October 31, 2024

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

TACE/HAIC

TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;

DRUG

PD-1/PD-L1 inhibits and anti-angiogenic agents

Agents were administrated based on the instructions recommended

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER

NCT06423144 - PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 | Biotech Hunter | Biotech Hunter